Arca
Skip to content
Tools
Tools

Bipolar disorder

Drug research and approvals for bipolar disorder: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 215 studies of bipolar disorder are recruiting on ClinicalTrials.gov, Health Canada has authorized 17 drug trials for it since 2013, and the EU has 2 authorised medicines for it.

  • Recruiting worldwide: 215
  • Trials authorized in Canada: 17
  • FDA orphan approvals: 0
  • EU medicines: 2

Recruiting now

Newest posted first, of 215 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 17

Phase 3 12 of 41

Phase 2 12 of 42

Phase 1 or earlier 12 of 14

How its trials ended

1,493 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 395 whose ending is known, 51% met their primary endpoint, 9% missed it and 39% stopped early.

  • Completed, result not reported70447%
  • Ongoing24817%
  • Met its primary endpoint20314%
  • Status unknown14610%
  • Stopped: other or unclear785%
  • Stopped: enrollment or feasibility383%
  • Missed its primary endpoint372%
  • Stopped: funding181%
  • Stopped: sponsor or business decision131%
  • Stopped: lack of efficacy5<1%
  • Stopped: safety3<1%

Trials authorized in Canada

The 10 newest of 17; search them all in Canada trials
Jun 11, 2026Optimizing the synergy between behavioural activation therapy and intravenous ketamine for treatment resistant depressionKetamineUniversity of Ottawa Institute of Mental Health ResearchPending
Mar 4, 2025Psilocybin-assisted therapy for treatment-resistant depression in bipolar ii disorder: a randomized controlled trialPsilocybin (PEX010)University of British ColumbiaOngoing
Aug 25, 2022A multi-region, multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating SEP-4199 controlled release (CR) for the treatment…Aramisulpride-esamisulpride (SEP-4199)Sumitomo PharmaClosed
Aug 25, 2022A 12-month open-label extension study to evaluate the long-term safety, tolerability, and effectiveness of SEP-4199 controlled release (CR) for the treatment…Aramisulpride-esamisulpride (SEP-4199)Sumitomo PharmaClosed
Aug 3, 2022Psilocybin assisted therapy for anxiety and mood disorders: a transdiagnostic open label clinical trial for improving well-being (pam-well)PsilocybinBrain and Cognition Discovery FoundationClosed
Dec 6, 2021A pilot, randomized, placebo-controlled trial evaluating the treatment of premenstrual dysphoric disorder with oral contraceptives in bipolar disorderDrospirenone - ethinyl estradiolDr Benicio FreyClosed
Jul 23, 2021Repeated ketamine infusions for treatment-resistant bipolar disorder: a randomized, double-blind, midazolam-controlled, phase II clinical trialKetamineUniversity Health NetworkOngoing
Jul 8, 2021Assessment of safety and feasibility of exablate neuro system to perform echo-focusing echo imaging in patients with treatment-resistant neurologic and…Definity (perflutren)InsightecPending
Feb 12, 2021Efficacy of cariprazine in improving cognitive functioning in euthymic patients with bipolar i disorder: a proof of concept randomized, double blind placebo…CariprazineUniversity of British ColumbiaClosed
Feb 4, 2020Clinical trial protocol title: investigation of regional brain lactate elevation in subjects with bipolar disorderHyperpolarized pyruvate (13C)Sunnybrook Research InstitutePending

Medicines authorised in the EU

Newest first
Feb 20, 2013AdasuveLoxapineFerrer Internacional S.A.EMA ↗
Sep 1, 2010SycrestAsenapineOrganon N.V.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.